VKTX Overview
Upcoming Projects (VKTX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (VKTX)
-
A Third Look: Discussing the results from the 52-week data from the Phase 2b VOYAGE Study of VK2809, a liver-selective thyroid hormone receptor beta agonist, in patients with NASH.
Ticker: VKTX
Executed On: Dec 16, 2024 at 02:30 PM EST -
A Second Look: Discussing the results from the 52-week data from the Phase 2b VOYAGE Study of VK2809, a liver-selective thyroid hormone receptor beta agonist, in patients with NASH.
Ticker: VKTX
Executed On: Dec 11, 2024 at 01:00 PM EST -
Discussing the results from the 52-week data from the Phase 2b VOYAGE Study of VK2809, a liver-selective thyroid hormone receptor beta agonist, in patients with NASH.
Ticker: VKTX
Executed On: Dec 10, 2024 at 01:00 PM EST -
A Third Look: Discussing the data presented at ObesityWeek 2024 from Viking Therapeutics's dual GLP-1/GIP agonist, VK2735.
Ticker: VKTX
Executed On: Nov 21, 2024 at 02:00 PM EST -
A Second Look: Discussing the data presented at ObesityWeek 2024 from Viking Therapeutics's dual GLP-1/GIP agonist, VK2735.
Ticker: VKTX
Executed On: Nov 20, 2024 at 12:30 PM EST -
Discussing the data presented at ObesityWeek 2024 from Viking Therapeutics's dual GLP-1/GIP agonist, VK2735.
Ticker: VKTX
Executed On: Nov 19, 2024 at 03:30 PM EST -
A Third Perspective Discussing the expanding market opportunity with regard to direct to consumer platforms in the pharmaceutical space.
Tickers: PFE, LLY, VKTX, HIMS
Executed On: Nov 05, 2024 at 02:15 PM EST -
A Second Perspective Discussing the expanding market opportunity with regard to direct to consumer platforms in the pharmaceutical space.
Tickers: PFE, LLY, VKTX, HIMS
Executed On: Sep 18, 2024 at 09:00 AM EDT -
Discussing the expanding market opportunity with regard to direct to consumer platforms in the pharmaceutical space.
Tickers: LLY, PFE, VKTX, HIMS
Executed On: Sep 17, 2024 at 09:00 AM EDT -
A Third Look: Investigating the Phase 1 clinical trial data for VK2735, an oral GLP-1 and GIP agonist being developed by Viking Therapeutics for the treatment of metabolic disorders such as obesity.
Ticker: VKTX
Executed On: May 15, 2024 at 04:00 PM EDT -
A Second Look: Investigating the Phase 1 clinical trial data for VK2735, an oral GLP-1 and GIP agonist being developed by Viking Therapeutics for the treatment of metabolic disorders such as obesity.
Ticker: VKTX
Executed On: May 07, 2024 at 10:00 AM EDT -
Investigating the Phase 1 clinical trial data for VK2735, an oral GLP-1 and GIP agonist being developed by Viking Therapeutics for the treatment of metabolic disorders such as obesity.
Ticker: VKTX
Executed On: Apr 30, 2024 at 05:30 PM EDT -
A third look at Viking therapeutics dual GLP-1/GIP Receptor Agonist, VK2735, and the results from the Phase 2 Venture trial of VK2735
Ticker: VKTX
Executed On: Mar 14, 2024 at 11:00 AM EDT -
A second look at Viking therapeutics dual GLP-1/GIP Receptor Agonist, VK2735, and the results from the Phase 2 Venture trial of VK2735
Ticker: VKTX
Executed On: Mar 13, 2024 at 05:00 PM EDT -
A look at Viking therapeutics dual GLP-1/GIP Receptor Agonist, VK2735, and the results from the Phase 2 Venture trial of VK2735
Ticker: VKTX
Executed On: Mar 05, 2024 at 05:00 PM EST -
Discussing Akero's recent announcement of their Phase 2b SYMMETRY study results evaluating efruxifermin (EFX) in patients with compensated cirrhosis due to NASH
Tickers: AKRO, MDGL, ENTB, VKTX
Executed On: Jan 10, 2024 at 05:15 PM EST -
A Second Opinion: A fresh look at the potential of Viking Therapeutics VK2809 for advanced NASH
Ticker: VKTX
Executed On: Jul 19, 2023 at 10:30 AM EDT -
A fresh look at the potential of Viking Therapeutics VK2809 for advanced NASH
Ticker: VKTX
Executed On: Jul 13, 2023 at 02:00 PM EDT -
A third look: Discussing the potential of Viking therapeutics dual GLP-1/GIP Receptor Agonist, VK2735, in development for the potential treatment of obesity and various metabolic disorders
Tickers: VKTX, LLY
Executed On: Apr 10, 2023 at 01:00 PM EDT -
A second look: Discussing the potential of Viking therapeutics dual GLP-1/GIP Receptor Agonist, VK2735, in development for the potential treatment of obesity and various metabolic disorders
Tickers: VKTX, LLY
Executed On: Apr 06, 2023 at 02:00 PM EDT -
Discussing the potential of Viking therapeutics dual GLP-1/GIP Receptor Agonist, VK2735, in development for the potential treatment of obesity and various metabolic disorders
Tickers: VKTX, LLY
Executed On: Apr 04, 2023 at 10:45 AM EDT
Upcoming & Overdue Catalysts (VKTX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (VKTX)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
